Skip to content

Based on the regulation of intestinal flora disturbance To explore the mechanism of traditional Chinese medicine exercise combined with energy restriction to regulate overweight/obese type glucose and lipid metabolism

Traditional Chinese exercise combined with energy restriction can improve the mechanism of overweight/obese glucose and lipid metabolism disorder by regulating intestinal mucosal barrier repair mediated by intestinal flora

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086866
Enrollment
Unknown
Registered
2024-07-12
Start date
2024-09-29
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overweight/Obesit

Interventions

Overweight/obese energy restriction group:Low calorie intake intervention
Overweight/obese in traditional Chinese medicine exercise group combined with energy restriction group (Bigu group):Traditional exercise combined with no energy intake intervention
Overweight/obese in traditional Chinese medicine exercise group combined with low energy restriction group:Traditional exercise combined with low energy intake intervention

Sponsors

Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. People who meet the diagnostic criteria for overweight/obesity or central obesity; 2. Age 18-40 years old; 3. Clear consciousness, no dementia, memory disorders and other consciousness problems; 4. Normal movement, no neuromuscular body diseases; 5. There is sufficient time for intervention; 6. Patients voluntarily participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have taken drugs that affect weight within the past 1 month or have undergone weight-loss surgery within 1 year; 2.Subjects who lost more than 5Kg in the past two months due to various causes; 3. Patients with secondary obesity who gain weight due to drugs, endocrine diseases or other diseases; 4. Combined with severe liver and kidney dysfunction or other serious primary diseases; 5. Obese patients with chronic diseases such as hypertension and hyperlipidemia; 6. Patients with various other chronic diseases who need to take medication for a long time and affect the test results; 7. Patients with gastrointestinal diseases, and those who used antibiotics, prebiotics and other drugs affecting intestinal flora 1 month before the test;

Design outcomes

Secondary

MeasureTime frame
Intestinal mucosal barrier function (DAO and ET levels);Body weight, BMI, and body composition indicators;Fasting blood glucose , blood lipid profile, insulin, and glycated hemoglobin;

Primary

MeasureTime frame
Changes in gut microbiota structure and function;Fecal metabolomic changes;

Countries

China

Contacts

Public ContactGuo Jianhong

Ningxia Medical University

guojh63@163.com+86 139 0958 6158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026